Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

  1. Moreau, P.
  2. Stewart, K.A.
  3. Dimopoulos, M.
  4. Siegel, D.
  5. Facon, T.
  6. Berenson, J.
  7. Raje, N.
  8. Berdeja, J.G.
  9. Orlowski, R.Z.
  10. Yang, H.
  11. Ma, H.
  12. Klippel, Z.
  13. Zahlten-Kumeli, A.
  14. Mezzi, K.
  15. Iskander, K.
  16. Mateos, M.-V.
Revue:
Cancer Medicine

ISSN: 2045-7634

Année de publication: 2020

Volumen: 9

Número: 9

Pages: 2989-2996

Type: Article

DOI: 10.1002/CAM4.2945 GOOGLE SCHOLAR lock_openAccès ouvert editor